This study was designed to find out whether concurrent administration of alfuzosin and tadalafil to patients with LUTS due to BPH improves the beneficial effects of each drug administered alone. As the prevalence of both LUTS and ED increases with age, physicians could be in a position to

manage both of these conditions simultaneously using these drugs. After approval from the institutional ethics committee and written informed consent from all participants, men > 50 years of age and International Prostate GDC-0068 purchase Symptom Score (IPSS) ≥ 8 were randomized to receive a 12-week treatment with either alfuzosin 10 mg once daily, tadalafil 10 mg once daily, or the combination of both. The study conformed to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000). Exclusion criteria

were according to the specified contraindications of both the drugs. Patients were advised to take alfuzosin each day after the same meal and tadalafil at bed time. Patients were assessed at baseline, 6 weeks and after 12 weeks of treatment. Subjective LUTS was assessed by IPSS total, IPSS-Storage subscore (IPSS-S) and IPSS-Voiding subscore (IPSS-V). Other AZD0530 chemical structure LUTS-related measurements included maximum urinary flow rate (Q max), post-void residual urine (PVR) volume and IPSS quality of life score. Erectile function was concurrently assessed by the erectile domain score (EDS, the sum of responses to questions 1–5 and 15) of the International Index of Erectile Function (IIEF). Safety was evaluated by noting the occurrence of side-effects due to the drug therapy. To summarize the result statistically, total number or percentage was reported. Normality of the measurable data was tested by Kolmogorov Smirnov test. All three groups were compared for normally distributed data by analysis of variance (anova) followed by post Hoc test student Newman Kuel procedure for pairwise comparison.

Within the same group the variables were compared by paired t-test and variables between the groups were compared using unpaired t-test. The skewed data were analyzed for all the three groups using Kruskal–Wallis test, anova followed by Mann–Whitney test for pairwise comparison. All the classified/categorical data were analyzed for all the three groups using χ2. A P-value < 0.05 was considered as significant. A total of 75 men were randomized to receive alfuzosin 10 mg once daily (n = 25), Fenbendazole tadalafil 10 mg once daily (n = 25), or the combination of both (n = 25) for 12 weeks. The patient disposition is summarized in Figure 1. All the patients completed the study. Patient baseline clinical characteristics are shown in Table 1. Overall baseline demographics and patient characteristics were similar across the treatment groups. International Prostate Symptom Score total, IPSS-S and IPSS-V significantly improved at 6 weeks in all three treatment groups (P < 0.001) but the improvement with the combination therapy was similar to alfuzosin (P = 0.121) but greater than tadalafil (P < 0.